SCM
CBIO

Sio Capital Management’s Crescent Biopharma CBIO Stock Holding History

Sio Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,555
Closed -$1.07M – 83
2021
Q1 		$1.07M Buy
+3,555
New +$1.27M 0.22% 80

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sio Capital Management's CBIO Position: Q2 2021 in Review

Sio Capital Management sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 3,555 shares — an estimated $1.07M sold.

Sio Capital Management first reported a position in CBIO in Q1 2021 and held it in 1 quarter. The position peaked at $1.07M in Q1 2021. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

  • Sio Capital Management reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
  • Sio Capital Management sold 3,555 Crescent Biopharma shares in Q2 2021, an estimated $1.07M.
  • Sio Capital Management first reported a position in Crescent Biopharma in Q1 2021 and held it in 1 quarter.
  • Sio Capital Management's Crescent Biopharma position peaked at $1.07M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on Sio Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.